-- Adherium Limited (ASX: ADR), a leading digital health company specialising in remote patient monitoring and data solutions for respiratory patients, confirms the first patients have been enrolled and remote patient monitoring underway as part of the SENTA’s commercial roll out of the Hailie® platform.
In September Adherium entered a partnership with SENTA (Southern Ear, Nose, Throat and Allergy), one of the largest, premier specialty allergy and asthma medical groups in the United States. The first patients are now being monitored and managed at SENTA clinics in Atlanta, Georgia.
Enrollment will expand and scale to more patients and providers into 2024 within SENTA’s 48 locations in six states with 88 specialist allergy, asthma and ENT physicians, physician assistants and nurse practitioners.
Hailie’s FDA 510(k) cleared advanced, drug agnostic sensors are the first to measure inhaler use and inspiratory flow rate. Adherium's state-of-the-art Hailie sensor technology and software platform empower patients and their doctors with information to improve adherence, reduce exacerbations and improve quality of life.
Hailie enables doctors to bill for long-term, remote patient management under established US reimbursement codes. Adherium is paid for sensor sales and receives monthly, per patient fees for generating and transmitting respiratory data.
